Experience

LifeScientis

• France
• Biotechnology
• 1 - 100 Employee

• Founder, President and CSO

  • Nov 2015 - 8 years 2 months

  Grasse LifeScientis, based in Provence Alpes Cote d'Azur, intends to answer to two major issues in the Life science industries : efficacy and safety of products use. LifeScientis has developed two complementary activities : 1) consulting activities in Toxicological hazard identification and risk evaluation and 2) Research and Development related to nano/mico-encapsulation of ingredients or active agents for targeted delivery purpose. The expertise in toxicology, and particularly in hazards and… Show more LifeScientis, based in Provence Alpes Cote d'Azur, intends to answer to two major issues in the Life science industries : efficacy and safety of products use. LifeScientis has developed two complementary activities : 1) consulting activities in Toxicological hazard identification and risk evaluation and 2) Research and Development related to nano/mico-encapsulation of ingredients or active agents for targeted delivery purpose. The expertise in toxicology, and particularly in hazards and risks connected to endocrine disruptions and nanotechnologies, allows to determine the safety (security) of use of molecules or devices, and to define in an optimal way the criteria to be set up in processes of selection. The expertise in the field of nanobiotechnologies, based on a soft chemistry, allows the company to set up products related to a passive and/or targeted delivery. This activity is based on proprietary projects and patents but also on partnerships with public research institutes and/or industries. These links allow the company to always propose a reactive and high-technology environment. LifeScientis ® is a privileged partner of pharmacy, cosmetic, perfume, agricultural chemistry and biotechnology industries. The thorough knowledge within the company related to research, pre-development and development processes, allows to support all the value chain of these industries. LifeScientis ®assumed objectives are to participate in the development of new approaches in biotechnology, nanobiotechnology and nanomedicine. This duality allows the company to support the development for users or patients of safe and effective products for its well-being, health and quality of its environment. Show less



Galderma

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Non Clinical Safety Unit Manager

  • Jan 2002 - May 2013

  In charge of the Safety Unit to asses toxic effects of NCE from early development to dossier filing. Management of scientists and operational managers teams (PhD, PharmD, DVM, MSc) working in three operational units. Responsible of the strategy definition an set up of operational units organization; implementation under Good Laboratory Practices (GLP) and ISO norms; Definition of human ressource, skill profile needs and workload mapping to support non-clinical safety… Show more In charge of the Safety Unit to asses toxic effects of NCE from early development to dossier filing. Management of scientists and operational managers teams (PhD, PharmD, DVM, MSc) working in three operational units. Responsible of the strategy definition an set up of operational units organization; implementation under Good Laboratory Practices (GLP) and ISO norms; Definition of human ressource, skill profile needs and workload mapping to support non-clinical safety activities. Definition and implementation of the non-clinical safety In/Outsourcing activities beakdown strategy to guarantee the operational and scientific needs for the company with identification of world wide preferred providers, including strategic partnership contract; Supervision of all operational and scientitifc activities linked to the toxicological and pharmakokinetic projects related to the safety profiling of new chemical entities. Review of non-clinical dossiers to support clinical studies and /or submission.and / or due diligence. Show less



Bayer Crop Science

• Morocco
• Farming
• 100 - 200 Employee

• Toxicologist-Unit Manager-Scientific Expert in Endocrine Disruption and Project Team Representative

  • Jan 2000 - Dec 2001

  Responsible of the endocrinology unit in charge of hormonal measurements in biological samples to asses endocrine disruption; Project Team Representative for the toxicological profiling and risk assessment of fungicide families during the pre development phases, including definition of specific program according to family specificity; Definition of specific programs to assess potential endocrine toxicity of chemical entities and responsible for international (EU) endocrinology… Show more Responsible of the endocrinology unit in charge of hormonal measurements in biological samples to asses endocrine disruption; Project Team Representative for the toxicological profiling and risk assessment of fungicide families during the pre development phases, including definition of specific program according to family specificity; Definition of specific programs to assess potential endocrine toxicity of chemical entities and responsible for international (EU) endocrinology research projects dedicated to the characterization of endocrine toxicity; Show less



Rhone Poulenc Agrochemical

• Toxicologist and Scientific expert in Endocrine disruption

  • Jan 1996 - Dec 1999

  As Scientific Expert in Endocine disruption : Participation to the OECD board to elaborate and validate Test Guidelines on the Endocrine Disrupters. Participation to the EU/US transatlantic Cooperation in Human Health on opportunities for collaborative EU/US research programmes Participation to European Workshop to adress element of the European Community Strategy for Endocrine disrupters Study Director and Sponsor Representative in Toxicology studies